For the first time, research shows that glioblastoma (GBM) is driven by two distinct subsets of cancer stem cells. Moreover, each subtype of glioma stem cells is driven by distinct transcriptional programs for growth and treatment resistance. The subsets also responded better to combination treatment in the mouse model.